While anthracyclines such as doxorubicin (DOX) are among the most effective chemotherapeutic agents and commonly used to treat pediatric cancers, they are problematic because they are associated with cardiotoxicity. With an overall survival rate for pediatric cancers of 70-90%, the number of young adults exposed to anthracyclines is steadily rising. In adults, this restricts the cumulative dose to 550mg/m2, but in children, the maximum cumulative dose must not exceed 300mg/m2. Even when treatment does not exceed this limit, heart failure can develop years after the initial exposure. Children are more vulnerable to anthracycline- induced myocardial impairment than adults, and the risk of heart failure increases the younger the age of the child at the time of anthracycline exposure. Unfortunately, heart failure may manifest years after initial exposure to anthracycline, when increased demand is placed on the heart such as during pregnancy or exercise. To understand this problem, we have established a mouse model of pediatric anthracycline cardiotoxicity and in this proposal we will investigate the mechanisms of late onset cardiotoxicity. We hypothesize that anthracyclines cause lasting damage to cardiomyocytes with resulting impaired contractile machinery or mitochondrial function. Anthracyclines exert their anti-tumor effect through negative effects on tumor angiogenesis;this is also the basis for hair loss during chemotherapy, as the vascular structures supporting the hair follicle involute. A key feature distinguishing children from adults is that the heart is still growing and must have matching angiogenesis to support the myocardium. We hypothesize that anthracyclines impair cardiac angiogenesis in the developing heart, thereby limiting the capacity to respond to increased demand, particularly as the heart grows. In light of recent work suggesting the possibility of cardiac- resident stem cells, we suggest that cardiac growth during childhood and possibly physiologic """"""""hypertrophy"""""""" during pregnancy may actually be due in part to the contribution of cardiac progenitor cells to increasing cardiac mass. We hypothesize that anthracyclines reduce the number of surviving bone marrow or cardiac stem cells, and thereby severely limit the growth potential of the young heart. While it is plausible that cardiac resident stem cells are actually bone marrow derived, the fact that mantle irradiation exacerbates the cardiotoxicity of anthracyclines supports the idea that the stem cells are already present in the heart in childhood, rather than migrating there in response to injury or increased demand. However, it is also possible that anthracyclines and mantle irradiation alter the heart so that it is a """"""""hostile environment"""""""" for bone marrow or cardiac-derived stem cells that would home to areas of injury, expand, and differentiate into cardiomyocytes and vascular elements in the myocardium. Stem cells are increasingly recognized to play a role in repair of the myocardium, including the vascular structures. We hypothesize that replenishing stem cells after anthracycline exposure will prevent the development of late-onset cardiotoxicity. This investigation will provide new understanding of DOX cardiotoxicity and potential therapy, and may also shed light on t role of stem cells in the response to increased cardiac workload.
Anthracycline-induced cardiotoxic effects are a serious problem among patients who survive childhood cancer and there is an urgent need to avoid such effects. Currently, satisfactory therapy for doxorubicin- induced cardiomyopathy is lacking and increased understanding of the molecular mechanisms of anthracycline action is necessary for the development of effective treatments against anthracycline-induced cardiotoxicity. This proposal establishes for the first time an animal model of childhood doxorubicin exposure leading to heart failure in adulthood, and will evaluate the effects of doxorubicin on cardiac stem cells.
|Sin, Jon; Mangale, Vrushali; Thienphrapa, Wdee et al. (2015) Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis. Virology 484:288-304|
|Xie, Yu; Collins, William J; Audeh, M William et al. (2015) Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. Curr Treat Options Cardiovasc Med 17:60|
|Robinson, Scott M; Tsueng, Ginger; Sin, Jon et al. (2014) Coxsackievirus B exits the host cell in shed microvesicles displaying autophagosomal markers. PLoS Pathog 10:e1004045|
|Sin, Jon; Puccini, Jenna M; Huang, Chengqun et al. (2014) The impact of juvenile coxsackievirus infection on cardiac progenitor cells and postnatal heart development. PLoS Pathog 10:e1004249|
|Kubli, Dieter A; Gustafsson, Asa B (2014) Cardiomyocyte health: adapting to metabolic changes through autophagy. Trends Endocrinol Metab 25:156-64|
|Hammerling, Babette C; Gustafsson, Åsa B (2014) Mitochondrial quality control in the myocardium: cooperation between protein degradation and mitophagy. J Mol Cell Cardiol 75:122-30|
|Jimenez, Rebecca E; Kubli, Dieter A; Gustafsson, Åsa B (2014) Autophagy and mitophagy in the myocardium: therapeutic potential and concerns. Br J Pharmacol 171:1907-16|
|Orogo, Amabel M; Gustafsson, Åsa B (2013) Cell death in the myocardium: my heart won't go on. IUBMB Life 65:651-6|
|Kubli, Dieter A; Gustafsson, Asa B (2012) Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res 111:1208-21|
|Tabor-Godwin, Jenna M; Tsueng, Ginger; Sayen, M Richard et al. (2012) The role of autophagy during coxsackievirus infection of neural progenitor and stem cells. Autophagy 8:938-53|
Showing the most recent 10 out of 16 publications